1st Quarter - Report

FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,070,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2026 $1,070,000 Replaced
1st Quarter - Amendment Jun 18, 2026 $1,100,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)

LobbyistCovered position, as disclosed
CRAIG BURTON —
SARAH CHRISTINE D'ORSIE —
STU EVENHAUGEN —
CHRISTOPHER LEIBUNDGUTH —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; Food & Drug Administration (FDA); SENATE

Medicare/Medicaid MMM

CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency

LobbyistCovered position, as disclosed
CRAIG BURTON —
SARAH CHRISTINE D'ORSIE —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); White House Office; HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL)

Health Issues HCR

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —
STU EVENHAUGEN —
CHRISTOPHER LEIBUNDGUTH —
STEVEN CHASE WALKER —

Contacted: U.S. Trade Representative (USTR); Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Labor, Dept of (DOL); Patent & Trademark Office (PTO); White House Office; Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); SENATE

Bills named: H.R. 3269 (119th), S. 2276 (119th), S. 2296 (119th)

Manufacturing MAN

Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)

LobbyistCovered position, as disclosed
CRAIG BURTON —
STU EVENHAUGEN —

Contacted: Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; Natl Economic Council (NEC); White House Office; Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

PTAB Proposed Rule - Restrict Use of IPR Patent Legislation Ancillary Product Patent Reform Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —
STEVEN CHASE WALKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines

LobbyistCovered position, as disclosed
CRAIG BURTON —
CHRISTOPHER LEIBUNDGUTH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.